Establishment of a humanized mouse model of keloid diseases following the migration of patient immune cells to the lesion: Patient

Experimental & Molecular Medicine (2023)Cite this article

219 Accesses

Metrics details

Keloid disorder is an abnormal fibroproliferative reaction that can occur on any area of skin, and it can impair the quality of life of affected individuals. To investigate the pathogenesis and develop a treatment strategy, a preclinical animal model of keloid disorder is needed. However, keloid disorder is unique to humans, and the development of an animal model of keloid disorder is highly problematic. We developed the patient-derived keloid xenograft (PDKX), which is a humanized mouse model, and compared it to the traditional mouse xenograft model (transplantation of only keloid lesions). To establish the PDKX model, peripheral mononuclear cells (PBMCs) from ten keloid patients or five healthy control subjects were injected into NOD/SCID/IL-2Rγnull mice, and their keloid lesions were grafted onto the back after the engraftment of immune cells (transplantation of keloid lesions and KP PBMCs or HC PBMCs). Four weeks after surgery, the grafted keloid lesion was subjected to histologic evaluation. Compared to the traditional model, neotissue formed along the margin of the grafted skin, and lymphocyte infiltration and collagen synthesis were significantly elevated in the PDKX model. The neotissue sites resembled the margin areas of keloids in several respects. In detail, the levels of human Th17 cells, IL-17, HIF-1a, and chemokines were significantly elevated in the neotissue of the PDKX model. Furthermore, the weight of the keloid lesion was increased significantly in the PDKX model, which was due to the proinflammatory microenvironment of the keloid lesion. We confirmed that our patient-derived keloid xenograft (PDKX) model mimicked keloid disorder by recapitulating the in vivo microenvironment. This model will contribute to the investigation of cellular mechanisms and therapeutic treatments for keloid disorders.

Although keloid lesions are benign, they display aggressive and uncontrolled growth and a high rate of recurrence. These lesions can occur on any area of skin; the most commonly affected sites are the anterior chest, shoulders, back, and earlobe1. In most cases, the affected sites are accompanied by pain, disfigurements, and pruritis, which can cause emotional distress and other psychosocial symptoms2.

The pathophysiology of keloid disorder is unclear, and effective treatments that do not induce recurrence are not available. The etiology may encompass both genetic and environmental factors. Cytokines such as transforming growth factor (TGF), insulin-like growth factor, and vascular endothelial growth factor are highly expressed in keloid tissue3. In addition, proinflammatory cytokines generated by chronic inflammation are associated with pathologic fibroproliferative responses in keloid tissue4,5.

To investigate the pathogenesis of keloid disorder and develop a treatment strategy, a preclinical animal model is needed. However, keloid lesions develop only in humans, and the development of animal models is problematic. To overcome this difficulty, the keloid xenograft model, in which keloid lesions are grafted onto the skin or in a subcutaneous pocket of an immune-deficient mouse, was developed6. In this model, the grafted keloid lesion remained viable for several weeks to months with evidence of angiogenesis and fibrosis7,8; this model has been applied extensively in keloid research9,10,11. However, because keloids lack T and B cells, the microenvironment may not reflect the inflammatory process of keloid disorder.

We developed a new humanized mouse model known as the patient-derived keloid xenograft (PDKX) model and compared it to the mouse xenograft model. To establish the PDKX model, peripheral blood mononuclear cells (PBMCs) from a keloid patient were injected into NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice and keloid tissue were grafted onto the back 4 weeks after immune cell transplantation. Four weeks after surgery, the grafted keloid tissue was subjected to histologic analysis.

This study was approved by the Institutional Review Board of Bucheon St. Mary’s Hospital (HC18TESI0013). Keloid lesions (n = 10) and PBMCs (n = 10) were obtained from 10 keloid patients who underwent surgery for ear keloid lesions. Healthy PBMCs (n = 5) were obtained from five healthy controls in this study. Informed consent was obtained from all patients according to the principles of the Declaration of Helsinki.

Eight-week-old NSG male mice were purchased from Jackson Laboratories (Bar Harbor, ME). All experimental procedures were approved by the Department of Laboratory Animals, Institutional Animal Care and Use Committee (IACUC) of the School of Medicine, Catholic University of Korea, and conformed with the guidelines of the United States National Institutes of Health (Permit Number: 2021-0027-02).

PBMCs were obtained from the blood of five healthy controls and ten keloid patients and intraperitoneally injected into NSG mice at a dose of 3 × 106/mouse. Two weeks after transplantation, a keloid lesion (0.5 cm3, 130–150 mg) was transplanted into the back under the panniculus carnosus muscle. In the control group, keloid lesions were transplanted without preoperative PBMC transplantation. Four weeks after tissue transplantation, the mice were euthanized, and the transplanted human keloid skin lesion was removed for histologic evaluation (Fig. 1a).

a Schematic representation of the humanized mouse model of keloid disorder. PBMCs isolated from the blood of keloid patients (KF, n = 10) and healthy controls (HC, n = 5) were injected intraperitoneally into NSG mice (3 × 106 cells per mouse). Two weeks later, the keloid lesion was transplanted into the back of the NSG mouse and observed for 4 weeks. b Peripheral blood samples of the mice have analyzed for human CD4+ T-cell engraftment by flow cytometry. c and d Four weeks after xenograft, the transplanted tissues were harvested, and the size and weight were measured. The bar graphs are from three independent experiments; means ± SDs. **p < 0.01.

Before transplantation and 4 weeks after skin tissue transplantation, the transplanted grafts were excised and subjected to morphologic analysis, as well as weight and size measurement using an electronic microbalance and ruler.

To confirm the engraftment of human immune cells in mouse blood, flow cytometry was performed. To confirm the engraftment of human CD4 T cells, mononuclear cells in mouse blood were stained with human anti-CD4-PeCy7 (Cat. no. 300511; Biolegend, San Diego, CA). Four weeks after tissue transplantation, IL-17-expressing human CD4+ T cells (Th17) were analyzed in the whole blood of mice. Mononuclear cells in mouse blood were stained with human anti-CD4 and IL-17-PE (12-7179-42; eBioscience, San Diego, CA). Before intracellular staining, the cells were stimulated for 4 h with phorbol myristate acetate (25 ng/mL) and ionomycin (250 ng/mL) in the presence of GolgiStop (554715; BD Biosciences, San Jose, CA). Intracellular staining was performed using a BD Cytofix/Cytoperm Plus Fixation/Permeabilization Kit and BD Golgistop Kit (554715; BD Biosciences). Flow cytometry was performed using a cytoFLEX flow cytometer (Beckman Coulter, Brea, CA), and the data was analyzed using FlowJo software (Tree Star, Ashland, OR).

Explanted tissue was subjected to histological analyses to evaluate inflammation and collagen density.

The grafted tissues were excised and fixed in 4% neutral buffered formalin for 24 h, embedded in paraffin, and sectioned at a thickness of 5-µm. The tissue slides were deparaffinized and stained with hematoxylin and eosin (H&E). Masson’s trichrome (MT) staining was performed to examine collagen deposition using a Masson’s trichrome staining kit (PolySciences, Inc., Warrington, PA)12,13. Inflammation in H&E-stained tissue sections was assigned an ordinal score from 0 to 3 for mononuclear cell infiltration (grade 0: none; grade 1: mild; grade 2: moderate; and grade 3: severe). Collagen in Masson’s trichrome-stained sections was quantified using ImageJ software.

The tissue sections were incubated at 4 °C with the following primary monoclonal antibodies: anti-HIF-1α (MA1-516; Thermo Fisher Scientific, Waltham, MA), anti-IL-17 (MAB3171-100; R&D Systems, Minneapolis, MN), anti-CD4 (ab133616; Abcam, Cambridge, UK), anti-IL-4 (PA5-25165; Thermo Fisher Scientific), anti-SDF-1 (ab9797; Abcam), anti-CCL2 (ab9669; Abcam), anti-CCL3 (PA5-47000; Thermo Fisher Scientific), anti-CXCL9 (ab9720; Abcam), anti-TGFβ (ab170874; Abcam), and anti-COL1A1 (PA5-50938; Thermo Fisher Scientific). Subsequently, the sections were exposed to horseradish peroxidase-coupled goat secondary antibodies conjugated to dextran (Dako, Glostrup, Denmark). The neotissue of sections was visualized using DAB + chromogen. Three slides were stained per sample of skin tissue; samples were taken at ≥500 µm intervals. The immunostained sections were examined using a photomicroscope (Olympus, Tokyo, Japan). The DAB-positive area was analyzed by color deconvolution with NIH ImageJ software.

CD4, IL-17, IL-4, pSTAT3 (y705), CXCR3, and procollagen levels were analyzed by confocal microscopy. Paraffin-embedded sections were incubated with 10% normal goat serum for 30 min and stained with anti-CD4 (AF-379-NA; R&D Systems), anti-IL-17 (MAB3171-100; R&D Systems), anti-IL-4 (PA5-25165; Thermo Fisher Scientific), anti-pSTAT3 (y705) (ab76315; Abcam), anti-CXCR3 (SC-133087; Santa Cruz Biotechnology, Dallas, TX), and anti-procollagen (ab64409; Abcam) antibodies. Next, the samples were reacted with anti-goat IgG-FITC (SC-2024; Santa Cruz Biotechnology), anti-mouse-IgG1-Alexa Fluor 555 (A21127; Invitrogen, Waltham, MA), anti-rabbit-IgG-PE (4050-09; Southern Biotech, Birmingham, AL), anti-rabbit-IgG APC (A-10931; Invitrogen), anti-mouse-IgG-Alexa Fluor 647 (1031-31; Southern Biotech), and anti-rat IgG-Alexa Fluor 488 (A-11006; Invitrogen)-conjugated secondary antibodies. Nuclei were stained with DAPI (D3571; Thermo Fisher Scientific). The sections were visualized using a confocal microscope (LSM 700; Carl Zeiss, Oberkochen, Germany); the colocalization area and intensity were analyzed using ZEN 2009 software (Carl Zeiss).

The results are presented as the means ± standard deviations (SD). Data were analyzed using Student’s t-test or the Mann‒Whitney U test with Prism 5 software (GraphPad, La Jolla, CA); p < 0.05 (two-tailed) was considered indicative of significance.

We generated a patient-derived PDKX model as described in the “Materials and methods” section (Fig. 1a). Two weeks after the injection of immune cells from keloid patients or healthy controls into NSG mice, we evaluated the engraftment levels of human CD4 T cells. Human-derived CD4+ T cells were identified in the blood of recipient mice. In both PDKX model models that were injected with keloid patient (KP) and healthy control (HC) PBMCs, CD4+ T cells were engrafted well. However, the level of engrafted CD4+ T cells was different in the KP PBMC and HC PBMC groups (Fig. 1b). Four weeks after tissue transplantation, the size, and weight of the transplanted tissue were analyzed, and the transplanted tissues were significantly larger in the KP PBMC (9.5 ± 5 mg)-injected group than in the HC PBMC (3.3 ± 2.3 mg)-injected group (Fig. 1c and d).

We found neotissue formation along the margin of the grafted skin tissue in the KP PBMC and HC PBMC groups. Interestingly, the neotissue of grafted skin showed the most abundant inflammatory cell infiltration and fibrosis in the KP PBMC group. The transplanted tissues in the KP PBMC PDKX model group had an increased collagen density and collagen bundle sizes (Fig. 2a). The number of CD4+IL-17+ T cells was significantly increased in KP PBMCs and keloid lesion-transplanted mice (Fig. 2b). We confirmed that neotissue formation along the margin of grafted skin and collagen synthesis was significantly elevated in our PDKX model.

a Representative images of transplanted keloid lesions stained with H&E and MT. Inflammation scores and integrated densities are shown. b Mononuclear cells from humanized mouse blood stained with human CD4-PeCy7 and human IL-17-PE. The frequency of human CD4+IL-17+ T cells is shown. The bar graphs are from three independent experiments; means ± SDs. *p < 0.05; **p < 0.01; ***p < 0.001.

IL-17 expression in T cells is increased in keloid patients and the transitional region of keloid lesions. The IL-17-STAT3-HIF-1α axis is involved in defective homeostasis and increased fibrosis in dermal fibroblasts, implicating IL-17/Th17 cells in keloid disease14. IL-4 and IL-17 promote inflammation and fibrosis in systemic sclerosis, pulmonary disease, and liver cirrhosis15,16,17. Therefore, we evaluated cytokine-expressing immune cells in keloid lesions transplanted with KP PBMCs. The numbers of cells expressing human IL-4, IL-17, and HIF1-α were increased in the perigraft area (Fig. 3a). The number of CD4+IL-17+ T cells was significantly increased in KP PBMCs and keloid lesion-transplanted mice. The numbers of pSTAT3705-positive CD4 T cells and CXCR3-positive CD4 T cells were significantly increased in the perigraft area in the KP PBMC group compared to the HC PBMC and control groups (Fig. 3b). Therefore, Th17 cell infiltration was significantly elevated in our PDKX model.

a Six weeks after the induction of humanized mice, the transplanted keloid lesions were harvested and analyzed by IHC using antibodies against human HIF-1α, CD4, IL-4, and IL-17. Representative IHC images (upper panels) and graphs (lower panels). b Harvested tissues were stained for CD4 (FITC), IL-17 (PE), pSTAT3y705 (PE), CXCR3 (white), or DAPI (blue). Representative confocal images (upper panels) and graphs (lower panels). Original magnification, ×400; scale bars, 100 μm. Bars represent positive cell numbers per high-power field (HPF); means ± SDs. *p < 0.05; **p < 0.01; ***p < 0.001.

SDF-1 expression is significantly elevated in the keloid margin area, enhancing the recruitment of Th17 cells5. We found that SDF-1, CCL2, CCL3, and CXCL9 expression was significantly increased in the perigraft area in the KP PBMC group (Fig. 4a and b). Chemokines promote inflammation and fibrosis in keloid disorders18. Activated fibroblasts and endothelial cells release CCL2, thereby recruiting monocytes and inducing the production of extracellular matrix. The CCL3 level is increased in the plasma of keloid patients19. Recruited monocytes also produce other chemokines, such as CXCL9, promoting the infiltration of CXCR3-expressing Th17 cells20. Therefore, increased levels of SDF-1 and CC chemokines contribute to the integrity of keloid lesions and promote fibrosis.

a and b Six weeks after the induction of humanized mice, the transplanted tissues were harvested and analyzed by IHC using antibodies against human SDF-1 CCL2, CCL3, and CXCL9. Representative IHC images and graphs. Original magnification, ×400; scale bars, 100 μm. Bars are positive cell numbers per HPF; means ± SDs. *p < 0.05; **p < 0.01; ***p < 0.001.

Procollagen is synthesized by fibroblasts and assembled into collagen fibrils21. TGF-β and collagen type I alpha 1 (COL1A1) are mediators of fibrosis in keloid patients22,23. Procollagen, TGF-β, and COL1A1 expression were significantly increased in the KP PBMC group (Fig. 5a and b). Therefore, our PDKX model accurately reflects chronic inflammation and allows in vivo growth of keloid tissue.

Six weeks after the induction of humanized mice, the transplanted tissues were harvested and analyzed by confocal microscopy and IHC. a The tissues were stained for procollagen (FITC) and DAPI (blue). Representative confocal images (upper panels) and graphs of areas of procollagen and DAPI colocalization (lower panels) are shown. b TGF-β and COL1A1 levels were evaluated by IHC. Representative IHC images (upper panels) and graphs (lower panels). Original magnification, ×400; scale bars, 100 μm. Bars are positive cell numbers per HPF; mean ± SD. *p < 0.05; **p < 0.01.

There is no single unifying hypothesis that adequately explains keloid formation; therefore, currently, available treatments include surgical excision and intralesional steroid treatment, but these treatments often induce recurrence24. To develop new treatments, greater insight into the molecular pathogenesis of keloid disorder is needed. However, keloid lesions only develop in humans, and so prior studies have used excised keloid lesions or fibroblasts25.

In in vivo transplantation-based models, immunodeficient animals (e.g., athymic mice) or an immune-privileged site (e.g., the cheek pouch of a hamster) are used because of the risk of rejection6,24. Shetlar6,7 described the implantation of keloid lesions into the subcutaneous tissue of athymic mice, and the implanted tissue maintained its integrity for >240 days without rejection. Subsequent keloid research was performed using similar animal models8,10,26.

However, these models do not recapitulate the disease microenvironment. The degree of inflammation and characteristics of fibroblasts can be different according to the lesion. For example, lymphocyte infiltration and proinflammatory cytokine (IL-17, IL-1β, IL-6, and tumor necrosis factor-α) expression are increased in the keloid margin area (growing margin) compared to the intralesional or extralesional areas (surrounding normal skin)5. Keloid fibroblasts from keloid margin sites show higher collagen I and III expression in vitro than those from intralesional or extralesional sites, and the paracrine effects of inflammatory cells on keloid fibroblasts contribute to disease progression27,28. Therefore, to reflect chronic inflammation in keloid disease, the keloid fibroblast–immune cell interaction needs to be modeled.

In this study, we injected T cells into NSG mice 2 weeks prior to the implantation of keloid lesions. Because human T cells were injected into immunocompromised mice, lethal xenogenic graft-versus-host disease (GVHD) could develop within 4–8 weeks29. The NSG mouse lacks major histocompatibility complex (MHC) classes I and II, extending the experimental period30. In a preliminary experiment, the mice survived for up to 12 weeks without GVHD, and fluorescence-activated cell sorting analysis showed successful engraftment of T cells in 4 weeks. We observed that the level of engrafted CD4+ T cells was significantly increased in the KP PBMC group. It has been reported that chimeric human T cells exhibit the phenotype of mature memory cells in a humanized SKID model31. In addition, memory T cell infiltration is abnormally present in the scar tissue of keloid patients32.

In our PDKX model, neotissue formed along the margin of the grafted skin, and lymphocyte infiltration and collagen synthesis were significantly elevated. The neotissue resembled the keloid margin area of keloids in several respects. First, SDF-1 and IL-17 expression was significantly elevated. Shin et al.33 reported high infiltration of SDF-1α + myofibroblasts into keloid margins, which was associated with increased recruitment of CXCR4-expressing immune cells and CXCR4-expressing fibrocytes. Additionally, IL-17 and SDF-1 expression was significantly elevated in the keloid margin area, upregulating SDF-1 and further increasing Th17-cell recruitment, creating a positive feedback loop and excessive fibrosis5.

Recently, it was reported that type 3 immunity (IL-17/Th17) is associated with progressive keloid disorder and that IL-17/Th17 induces inflammation and fibrosis in keloid fibroblasts through STAT3/HIF-1α5,34,35.

Furthermore, the inflammatory niche-driven IL-17/IL-6 axis is associated with the acquisition by keloid-derived precursor cells of a tumor-like stem cell phenotype36. Therefore, IL-17 is important in the pathogenesis of keloids. However, SDF-1 and IL-17 expression was low in the perigraft area in the control group, whereas Th17 cell infiltration and SDF-1 expression were significantly elevated in our PDKX model.

Second, the expression of CC chemokines was significantly elevated in neotissue in the PDKX model. CCL2 stimulates the expression of collagen by fibroblasts and is implicated in renal fibrosis, ischemic cardiomyopathy, atherosclerosis, and pancreatitis37,38,39. CCL2 and CCR2 expression is reportedly enhanced in keloid tissue, increasing fibroblast proliferation18. Additionally, CCL3, CCL4, G-CSF, and GM-CSF levels were significantly elevated in the plasma of keloid patients compared to healthy controls, implicating inflammatory cytokines in the formation of keloid lesions19. In this study, CCL2 and CCL3 expression was significantly elevated in the perigraft and intragraft areas, contributing to keloid-lesion integrity and augmenting fibrosis. Monocyte chemokines such as CXCL9 promote the infiltration of CXCR3-expressing Th17 cells20.

Because keloid disorder is a chronic fibroproliferative disorder, the maintenance or growth of scar tissue in vivo is important. However, Kischer et al. 8,40 showed that the size of keloid lesions decreased (slope −0.736) after implantation on the back of an athymic nude mouse, and the volume of keloid lesions decreased by half after 67 days. Waki et al. 9 reported that grafts grew rapidly for 4 weeks after implantation and decreased in size thereafter. In this study, the weight of keloid lesions did not change significantly but increased significantly (~1.5-fold) in the keloid + KP PBMC group. This proinflammatory microenvironment is likely responsible for the increase in graft weight. Additionally, the allogeneic immune response was not seen as a concern because the inflammatory response was not found to be significantly higher in the normal PBMC (peripheral blood mononuclear cell) group than in the patient PBMC group.

In conclusion, our PDKX model reflects chronic inflammation in keloid lesions and enables their growth in vivo. This model will contribute to keloid research by recapitulating the in vivo microenvironment.

Tan, S., Khumalo, N. & Bayat, A. Understanding keloid pathobiology from a quasi-neoplastic perspective: less of a scar and more of a chronic inflammatory disease with cancer-like tendencies. Front. Immunol. 10, 1810 (2019).

Article CAS PubMed PubMed Central Google Scholar

Ud-Din, S. & Bayat, A. New insights on keloids, hypertrophic scars, and striae. Dermatol. Clin. 32, 193–209 (2014).

Article CAS PubMed Google Scholar

Shih, B. & Bayat, A. Genetics of keloid scarring. Arch. Dermatol. Res. 302, 319–339 (2010).

Article CAS PubMed Google Scholar

Sandulache, V. C., Parekh, A., Li-Korotky, H., Dohar, J. E. & Hebda, P. A. Prostaglandin E2 inhibition of keloid fibroblast migration, contraction, and transforming growth factor (TGF)-beta1-induced collagen synthesis. Wound Repair Regen. 15, 122–133 (2007).

Article PubMed Google Scholar

Lee, S. Y. et al. IL-17 induced stromal cell-derived factor-1 and profibrotic factor in keloid-derived skin fibroblasts via the STAT3 pathway. Inflammation 43, 664–672 (2020).

Article CAS PubMed Google Scholar

Shetlar, M. R., Shetlar, C. L., Hendricks, L. & Kischer, C. W. The use of athymic nude mice for the study of human keloids. Proc. Soc. Exp. Biol. Med. 179, 549–552 (1985).

Article CAS PubMed Google Scholar

Shetlar, M. R., Shetlar, C. L., Kischer, C. W. & Pindur, J. Implants of keloid and hypertrophic scars into the athymic nude mouse: changes in the glycosaminoglycans of the implants. Connect. Tissue Res. 26, 23–36 (1991).

Article CAS PubMed Google Scholar

Kischer, C. W., Pindur, J., Shetlar, M. R. & Shetlar, C. L. Implants of hypertrophic scars and keloids into the nude (athymic) mouse: viability and morphology. J. Trauma 29, 672–677 (1989).

Article CAS PubMed Google Scholar

Waki, E. Y., Crumley, R. L. & Jakowatz, J. G. Effects of pharmacologic agents on human keloids implanted in athymic mice. A pilot study. Arch. Otolaryngol. Head Neck Surg. 117, 1177–1181 (1991).

Article CAS PubMed Google Scholar

Tang, Z. et al. Wubeizi ointment suppresses keloid formation through modulation of the mTOR pathway. Biomed. Res. Int. 2020, 3608372 (2020).

Article PubMed PubMed Central Google Scholar

Ishiko, T. et al. Chondroitinase injection improves keloid pathology by reorganizing the extracellular matrix with regenerated elastic fibers. J. Dermatol. 40, 380–383 (2013).

Article CAS PubMed Google Scholar

Herndon, D. et al. Reduced postburn hypertrophic scarring and improved physical recovery with yearlong administration of oxandrolone and propranolol. Ann. Surg. 268, 431–441 (2018).

Article PubMed Google Scholar

Lemaire, R. et al. Resolution of skin fibrosis by neutralization of the antifibrinolytic function of plasminogen activator inhibitor 1. Arthritis Rheumatol. 68, 473–483 (2016).

Article CAS PubMed Google Scholar

Lee, S. Y. et al. IL-17 Induces autophagy dysfunction to promote inflammatory cell death and fibrosis in keloid fibroblasts via the STAT3 and HIF-1alpha dependent signaling pathways. Front. Immunol. 13, 888719 (2022).

Article CAS PubMed PubMed Central Google Scholar

Lei, L. et al. Th17 cells and IL-17 promote the skin and lung inflammation and fibrosis process in a bleomycin-induced murine model of systemic sclerosis. Clin. Exp. Rheumatol. 34, 14–22 (2016).

PubMed Google Scholar

Hammerich, L., Heymann, F. & Tacke, F. Role of IL-17 and Th17 cells in liver diseases. Clin. Dev. Immunol. 2011, 345803 (2011).

Article PubMed Google Scholar

Pignatti, P. et al. Role of the chemokine receptors CXCR3 and CCR4 in human pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 173, 310–317 (2006).

Article CAS PubMed Google Scholar

Nirodi, C. S. et al. Chemokine and chemokine receptor expression in keloid and normal fibroblasts. Wound Repair Regen. 8, 371–382 (2000).

Article CAS PubMed PubMed Central Google Scholar

Nangole, F. W., Ouyang, K., Anzala, O., Ogengo, J. & Agak, G. W. Multiple cytokines elevated in patients with keloids: is it an indication of auto-inflammatory disease? J. Inflamm. Res. 14, 2465–2470 (2021).

Article PubMed PubMed Central Google Scholar

Steinmetz, O. M. et al. CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis. J. Immunol. 183, 4693–4704 (2009).

Article CAS PubMed Google Scholar

Friedman, D. W. et al. Regulation of collagen gene expression in keloids and hypertrophic scars. J. Surg. Res. 55, 214–222 (1993).

Article CAS PubMed Google Scholar

Pan, X., Chen, Z., Huang, R., Yao, Y. & Ma, G. Transforming growth factor beta1 induces the expression of collagen type I by DNA methylation in cardiac fibroblasts. PLoS ONE 8, e60335 (2013).

Article CAS PubMed PubMed Central Google Scholar

Jagadeesan, J. & Bayat, A. Transforming growth factor beta (TGFbeta) and keloid disease. Int. J. Surg. 5, 278–285 (2007).

Article PubMed Google Scholar

Seo, B. F., Lee, J. Y. & Jung, S. N. Models of abnormal scarring. Biomed. Res. Int. 2013, 423147 (2013).

Article PubMed PubMed Central Google Scholar

Supp, D. M. Animal models for studies of keloid scarring. Adv. Wound Care (New Rochelle) 8, 77–89 (2019).

Article PubMed Google Scholar

Choi, M. H., Kim, J., Ha, J. H. & Park, J. U. A selective small-molecule inhibitor of c-Met suppresses keloid fibroblast growth in vitro and in a mouse model. Sci. Rep. 11, 5468 (2021).

Article CAS PubMed PubMed Central Google Scholar

Syed, F. et al. Fibroblasts from the growing margin of keloid scars produce higher levels of collagen I and III compared with intralesional and extralesional sites: clinical implications for lesional site-directed therapy. Br. J. Dermatol. 164, 83–96 (2011).

Article CAS PubMed Google Scholar

Ashcroft, K. J., Syed, F. & Bayat, A. Site-specific keloid fibroblasts alter the behaviour of normal skin and normal scar fibroblasts through paracrine signalling. PLoS ONE 8, e75600 (2013).

Article PubMed PubMed Central Google Scholar

Walsh, N. C. et al. Humanized mouse models of clinical disease. Annu. Rev. Pathol. 12, 187–215 (2017).

Article CAS PubMed Google Scholar

King, M. A. et al. Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex. Clin. Exp. Immunol. 157, 104–118 (2009).

Article CAS PubMed PubMed Central Google Scholar

Tary-Lehmann, M. & Saxon, A. Human mature T cells that are anergic in vivo prevail in SCID mice reconstituted with human peripheral blood. J. Exp. Med. 175, 503–516 (1992).

Article CAS PubMed Google Scholar

Li, Y. et al. The polygenic map of keloid fibroblasts reveals fibrosis-associated gene alterations in inflammation and immune responses. Front. Immunol. 12, 810290 (2021).

Article CAS PubMed Google Scholar

Shin, J. U. et al. TSLP is a potential initiator of collagen synthesis and an activator of CXCR4/SDF-1 axis in keloid pathogenesis. J. Investig. Dermatol. 136, 507–515 (2016).

Article CAS PubMed Google Scholar

Wang, Z. C. et al. The roles of inflammation in keloid and hypertrophic scars. Front. Immunol. 11, 603187 (2020).

Article CAS PubMed PubMed Central Google Scholar

Zhang, J. et al. IL-17 promotes scar formation by inducing macrophage infiltration. Am. J. Pathol. 188, 1693–1702 (2018).

Article CAS PubMed Google Scholar

Zhang, Q. et al. Tumor-like stem cells derived from human keloid are governed by the inflammatory niche driven by IL-17/IL-6 axis. PLoS ONE 4, e7798 (2009).

Article PubMed PubMed Central Google Scholar

Tesch, G. H. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am. J. Physiol. Renal Physiol. 294, F697–F701 (2008).

Article CAS PubMed Google Scholar

Marra, F. Renaming cytokines: MCP-1, major chemokine in pancreatitis. Gut 54, 1679–1681 (2005).

Article CAS PubMed PubMed Central Google Scholar

Xia, Y. & Frangogiannis, N. G. MCP-1/CCL2 as a therapeutic target in myocardial infarction and ischemic cardiomyopathy. Inflamm. Allergy Drug Targets 6, 101–107 (2007).

Article CAS PubMed Google Scholar

Kischer, C. W., Sheridan, D. & Pindur, J. Use of nude (athymic) mice for the study of hypertrophic scars and keloids: vascular continuity between mouse and implants. Anat. Rec. 225, 189–196 (1989).

Article CAS PubMed Google Scholar

Download references

This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (No. 2020R1F1A1075541), a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HV22C0069) and a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number HI20C1496).

These authors contributed equally: A Ram Lee, Seon-Yeong Lee.

These authors jointly supervised this work: Jung Ho Lee, Mi-La Cho.

Lab of Translational ImmunoMedicine, Catholic Research Institute of Medical Science, College of Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea

A Ram Lee, Seon-Yeong Lee, Jeong Won Choi, In Gyu Um, Hyun Sik Na & Mi-La Cho

Department of Biomedicine & Health Sciences, College of Medicine, The Catholic University of Korea, Seoul, South Korea

A Ram Lee, In Gyu Um, Hyun Sik Na & Mi-La Cho

The Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seoul, South Korea

A Ram Lee, Seon-Yeong Lee, Jeong Won Choi, In Gyu Um, Hyun Sik Na & Mi-La Cho

Department of Plastic and Reconstructive Surgery, College of Medicine, The Catholic University of Korea, Seoul, South Korea

Jung Ho Lee

Department of Medical Life Sciences, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul, 06591, South Korea

Mi-La Cho

You can also search for this author in PubMed Google Scholar

A.R.M., J.W.C., J.H.L., and M.-L.C. designed the experiments and analyzed the data. A.R.M., S.-Y.L., J.H.L., and M.-L.C. wrote the manuscript. The in vitro experiments were performed by A.R.M., J.W.C., and I.G.U. J.W.C., H.S.N., and I.G.U. conducted the IHC experiments. All authors critically reviewed and approved the final version of the manuscript.

Correspondence to Jung Ho Lee or Mi-La Cho.

The authors declare no competing interests.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

Lee, A.R., Lee, SY., Choi, J.W. et al. Establishment of a humanized mouse model of keloid diseases following the migration of patient immune cells to the lesion: Patient-derived keloid xenograft (PDKX) model. Exp Mol Med (2023). https://doi.org/10.1038/s12276-023-01045-6

Download citation

Received: 04 November 2022

Accepted: 24 April 2023

Published: 01 August 2023

DOI: https://doi.org/10.1038/s12276-023-01045-6

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative